TransMedics Group falls after tightening annual revenue forecast range, names new CFO

TransMedics

02/12/2024 21:43

** Medtech company TransMedics Group's  TMDX.O  shares fall
10.72% to $76.01 after market
    ** Company forecasts full-year revenue to be between $428
mln and $432 mln, vs prior range of $425 mln to $445 mln
    ** Analysts expect 2024 revenue of $432.36 mln, according to
data compiled by LSEG
    ** Company names Gerardo Hernandez as chief financial
officer, succeeding Stephen Gordon
    ** Hernandez most recently served as vice president finance,
head of corporate financial planning and analysis at Alnylam
Pharmaceuticals  ALNY.O 
    ** As of last close, TransMedics shares up ~8% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))